Back to search

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.

Data up to Jan 2025

Published1996
Citations140
References18

Total Citations Per Year

Abstract

References (18)

Participation of p53 protein in the cellular response to DNA damage.

1991 • 3,818 citations

Proposals for the classification of the myelodysplastic syndromes

1982 • 3,616 citations

Molecular themes in oncogenesis

1991 • 1,663 citations

Clinical Implications of the p53 Tumor-Suppressor Gene

1993 • 1,341 citations

Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?

1993 • 1,306 citations

Presence of a Potent Transcription Activating Sequence in the p53 Protein

1990 • 811 citations

Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene

1990 • 644 citations

Wild-type p53 can down-modulate the activity of various promoters.

1991 • 461 citations

p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis

1996 • 294 citations

p53 in hematologic malignancies

1994 • 269 citations

Human p53 gene localized to short arm of chromosome 17

1986 • 222 citations

Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages

1994 • 179 citations

Separation of synthetic phosphorothioate oligodeoxynucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange high-performance liquid chromatography

1992 • 73 citations

Expression of the p53 oncogene in acute myeloblastic leukemia.

1986 • 55 citations

Selective Cytotoxicity to Human Leukemic Myeloblasts Produced by Oligodeoxyribonucleotide Phosphorothioates Complementary to p53 Nucleotide Sequences

1994 • 48 citations

A denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations

1993 • 42 citations

OMA-AML-1: a leukemic myeloid cell line with CD34+ progenitor and CD15+ spontaneously differentiating cell compartments

1992 • 9 citations

Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia.

1994 • 6 citations

Cited By (0)

No citing papers found in database

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. (1996) – Journal of Clinical Oncology | Metascience Observatory Explorer